Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TVTX 
Travere Therapeutics Inc (TVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: TVTX (5-star) is a STRONG-BUY. BUY since 25 days. Simulated Profits (33.16%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $36
1 Year Target Price $36
| 11 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 93.34% | Avg. Invested days 33 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.09B USD | Price to earnings Ratio - | 1Y Target Price 36 |
Price to earnings Ratio - | 1Y Target Price 36 | ||
Volume (30-day avg) 15 | Beta 0.79 | 52 Weeks Range 12.91 - 28.69 | Updated Date 09/15/2025 |
52 Weeks Range 12.91 - 28.69 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -50.64% | Operating Margin (TTM) -11.05% |
Management Effectiveness
Return on Assets (TTM) -19.28% | Return on Equity (TTM) -705.73% |
Valuation
Trailing PE - | Forward PE 19.16 | Enterprise Value 2172120655 | Price to Sales(TTM) 6.27 |
Enterprise Value 2172120655 | Price to Sales(TTM) 6.27 | ||
Enterprise Value to Revenue 6.51 | Enterprise Value to EBITDA -5.67 | Shares Outstanding 89138704 | Shares Floating 79287067 |
Shares Outstanding 89138704 | Shares Floating 79287067 | ||
Percent Insiders 0.75 | Percent Institutions 117.52 |
Upturn AI SWOT
Travere Therapeutics Inc
Company Overview
History and Background
Travere Therapeutics Inc. was founded in 2011. Originally known as Lumena Pharmaceuticals, it rebranded to Travere Therapeutics in 2014. The company focuses on developing and commercializing therapies for rare diseases.
Core Business Areas
- Renal Disease: Development and commercialization of therapies for rare renal diseases, including focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).
- Other Rare Diseases: Exploring therapies for other rare diseases with unmet medical needs.
Leadership and Structure
Eric Dube serves as the CEO. The company has a typical organizational structure for a publicly traded biopharmaceutical company, with departments focused on research & development, clinical operations, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Filspari (sparsentan): Filspari is approved for the treatment of IgA nephropathy. The US market size for IgAN treatments is estimated to grow significantly in the coming years. Competitors include Calliditas Therapeutics (TARPEYO) and other potential entrants developing novel therapies. Current revenues are growing but not yet dominant in the market. Calliditas Therapeutics is the main competitor. Market share is growing. Number of users or revenue from this product is unavailable.
- Cholbam (cholic acid): Cholbam is approved for the treatment of bile acid synthesis disorders and peroxisomal disorders. There is no readily available market share data for Cholbam. Competing options depend on the specific condition being treated.
Market Dynamics
Industry Overview
The rare disease market is characterized by high unmet needs, regulatory incentives, and premium pricing. It is a growing market, driven by increasing awareness of rare diseases and advances in genetic research.
Positioning
Travere Therapeutics Inc. is positioned as a player in the rare disease space, specifically focusing on renal and metabolic disorders. Its competitive advantage lies in its focus on specific niche areas and the potential for accelerated approval pathways for rare disease therapies.
Total Addressable Market (TAM)
The total addressable market for rare kidney diseases is estimated in the billions of dollars globally. Travere is positioning itself to capture a significant share of this TAM, particularly in IgAN.
Upturn SWOT Analysis
Strengths
- Approved therapies addressing unmet needs
- Focused pipeline in rare diseases
- Experienced management team
- Regulatory advantages for rare disease therapies
Weaknesses
- Reliance on a limited number of products
- Competition from established pharmaceutical companies
- Dependence on successful clinical trials
- Potential for generic competition
Opportunities
- Expansion of existing therapies to new indications
- Acquisition of additional rare disease assets
- Partnerships with other pharmaceutical companies
- Geographic expansion
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from new therapies
- Pricing pressures
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- KDNY
- CLLS
- VTRS
Competitive Landscape
Travere Therapeutics Inc. faces competition from established pharmaceutical companies with greater resources. Its advantages include its focus on specific niche areas and its expertise in developing and commercializing rare disease therapies. Disadvantages include the reliance on a limited product portfolio and the potential for competition from generic drugs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the approval and commercialization of its therapies. Growth rates have varied depending on product adoption and market dynamics.
Future Projections: Future growth depends on the successful commercialization of existing products, the development of new therapies in its pipeline, and potential acquisitions. Analyst estimates vary, but generally project revenue growth in the coming years.
Recent Initiatives: Recent initiatives include expanding the commercial reach of Filspari, advancing its pipeline of rare disease therapies, and exploring potential strategic partnerships.
Summary
Travere Therapeutics is a growing biopharmaceutical company focused on rare diseases, with promising therapeutics like Filspari. The company's future success hinges on its ability to expand the market for existing drugs and develop new therapies, while navigating competitive threats. Financial performance depends heavily on successful clinical trials and effective commercialization strategies. Travere needs to actively explore expanding its portfolio and manage competitive pressures within the rare disease market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Travere Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-11-08 | President, CEO & Director Dr. Eric M. Dube Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 385 | Website https://www.travere.com |
Full time employees 385 | Website https://www.travere.com | ||
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.